Pre DiabetesNCT07650513
Awareness of Prediabetes Among Physicians
An observational study of Pre Diabetes and Awarness of Physcian About Prediabetes, run by Sohag University at 1 site in Egypt.
Trial summary
Prediabetes is associated with impaired fasting glucose and/or impaired glucose tolerance. Recent data indicate that more than one-third of adults in affluent countries have prediabetes . Read more about this study
- Who is it for?
- Ages 25 years and older
- Conditions the study is for
- Pre Diabetes, Awarness of Physcian About Prediabetes
- How many people
- 500 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2026to 30 Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 years and older
- All sexes
- Adult, Older adult
Study population: physicians (faculty medical staff) at Sohag government hospitals and clinics, Egypt (target n=500, all specialties and training levels).
Who may be able to join
- - Physicians working at Sohag government hospitals and clinics
- Faculty medical staff (any specialty)
- Willing to complete the self-administered questionnaire
- Provide informed written consent to participate in the study
Who cannot join
- 1 - Physicians who decline to provide informed consent.
- 2-Physicians who do not complete at least 90% of the questionnaire items.
- 3-Physicians not actively practicing at a Sohag government hospital or clinic during the study period.
Trial locations and contacts
1 site in 1 country.
About this study
Prediabetes is associated with impaired fasting glucose and/or impaired glucose tolerance. Recent data indicate that more than one-third of adults in affluent countries have prediabetes . Fasting glucose concentrations of 100-125 mg/dL, hemoglobin A1c (HbA1c) titers of 5.7-6.4%, and two-hour post-stimulus glucose levels of 140-199 mg/dL are used to identify prediabetes. Behavioral lifestyle changes and medications are useful in preventing the progression of prediabetes to T2DM .
Early detection and treatment of T2DM and prediabetes can prevent future health problems. However, many people with metabolic disorders are undiagnosed, partly due to the clinical practices and knowledge of primary care physicians (PCPs). PCPs play a critical role in diabetes prevention through the detection and management of prediabetes. Successful screening initiatives and the start of appropriate management interventions depend on PCPs' level of prediabetes knowledge Most patients with prediabetes do not receive evidence-based preventive care from their PCPs . Systemic barriers hinder physicians' ability to provide the best evidence-based practice, such as performance measures, insurance reimbursement, cultural expectations, and a lack of tools and staffing resources
- Medical subject headings
- Glucose Intolerance
What is being measured
The primary outcome is the main question the study is designed to answer.
Physician awareness of prediabetes risk factors, diagnostic criteria, and management recommendations
Proportion of physicians who correctly identify: (1) risk factors for diabetes screening (e.g., age ≥35, BMI ≥25 kg/m², hypertension, family history of diabetes), (2) fasting glucose diagnostic cut-offs for prediabetes (100-125 mg/dL) and diabetes (≥126 mg/dL), (3) HbA1c cut-offs for prediabetes (5.7-6.4%) and diabetes (≥6.5%), (4) lifestyle modification recommendations for prediabetes (minimum 7% weight loss and 150 minutes of physical activity per week), and (5) appropriate use of metformin for prediabetes prevention.Validated structured self-administered questionnaire (adapted from Tseng et al., 2019) distributed via Google Forms, including multiple-choice and true/false questions
Measured: Single time point during data collection period (April 1, 2026 to June 30, 2026)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2026
- Study start1 Apr 2026
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pre DiabetesStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hany Ahmed Mohamed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07650513
- Sponsor's protocol ID
- Soh-Med-26-5--10PD
- Status last verified
- Apr 2026
- First submitted
- 10 Jun 2026
- Last updated
- 16 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Awareness of Prediabetes Among Physicians
- ClinicalTrials.gov ID
- NCT07650513
- Acronym / sponsor ID
- Soh-Med-26-5--10PD
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 16 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prediabetes is associated with impaired fasting glucose and/or impaired glucose tolerance. Recent data indicate that more than one-third of adults in affluent countries have prediabetes . Fasting glucose concentrations of 100-125 mg/dL, hemoglobin A1c (HbA1c) titers of 5.7-6.4%, and two-hour post-stimulus glucose levels of 140-199 mg/dL are used to identify prediabetes. Behavioral lifestyle changes and medications are useful in preventing the progression of prediabetes to T2DM .
Early detection and treatment of T2DM and prediabetes can prevent future health problems. However, many people with metabolic disorders are undiagnosed, partly due to the clinical practices and knowledge of primary care physicians (PCPs). PCPs play a critical role in diabetes prevention through the detection and management of prediabetes. Successful screening initiatives and the start of appropriate management interventions depend on PCPs' level of prediabetes knowledge Most patients with prediabetes do not receive evidence-based preventive care from their PCPs . Systemic barriers hinder physicians' ability to provide the best evidence-based practice, such as performance measures, insurance reimbursement, cultural expectations, and a lack of tools and staffing resources
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 25 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- physicians (faculty medical staff) at Sohag government hospitals and clinics, Egypt (target n=500, all specialties and training levels).
Key inclusion criteria (4 listed)
- - Physicians working at Sohag government hospitals and clinics
- Faculty medical staff (any specialty)
- Willing to complete the self-administered questionnaire
- Provide informed written consent to participate in the study
Key exclusion criteria (3 listed)
- 1 - Physicians who decline to provide informed consent.
- 2-Physicians who do not complete at least 90% of the questionnaire items.
- 3-Physicians not actively practicing at a Sohag government hospital or clinic during the study period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Physician awareness of prediabetes risk factors, diagnostic criteria, and management recommendations
Time frame: Single time point during data collection period (April 1, 2026 to June 30, 2026)
Proportion of physicians who correctly identify: (1) risk factors for diabetes screening (e.g., age ≥35, BMI ≥25 kg/m², hypertension, family history of diabetes), (2) fasting glucose diagnostic cut-offs for prediabetes (100-125 mg/dL) and diabetes (≥126 mg/dL), (3) HbA1c cut-offs for prediabetes (5.7-6.4%) and diabetes (≥6.5%), (4) lifestyle modification recommendations for prediabetes (minimum 7% weight loss and 150 minutes of physical activity per week), and (5) appropriate use of metformin for prediabetes prevention.Validated structured self-administered questionnaire (adapted from Tseng et al., 2019) distributed via Google Forms, including multiple-choice and true/false questions
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Pre Diabetes
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
RecruitingObservational study
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Overweight, Prediabetic State
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pre Diabetes and Awarness of Physcian About Prediabetes, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physician awareness of prediabetes risk factors, diagnostic criteria, and management recommendations (time frame: Single time point during data collection period (April 1, 2026 to June 30, 2026)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2026.